Condition : Osteoarthritis, Knee Intervention : Procedure: Unlimited postoperative weightbearing Sponsors : Northern Orthopaedic Division, Denmark; Northern Orthopaedic Division, Denmark Active, not r...

Condition : Arthritis, Juvenile Rheumatoid Intervention : Drug: ACZ885 Sponsor : Novartis Completed - verified August 2011

Condition : Arthritis, Juvenile Rheumatoid Intervention : Drug: ACZ885 Sponsor : Novartis Completed - verified August 2011

Condition : Rheumatoid Arthritis Interventions : Drug: rituximab [MabThera/Rituxan]; Drug: Methotrexate Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Completed - verified September 2013

Condition : Rheumatoid Arthritis Interventions : Drug: rituximab [MabThera/Rituxan]; Drug: Methotrexate Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Completed - verified September 2013

Condition : Rheumatoid Arthritis Interventions : Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan] Sponsors : Hoffmann-La Roche; Hoffmann-La Ro...

Condition : Rheumatoid Arthritis Interventions : Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan] Sponsor : Hoffmann-La Roche Active, not recr...

Conditions : Osteoarthritis; Chronic Pain Interventions : Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release); Drug: Placebo Sponsors : Pfizer; Pfizer Completed - verified S...

Subjects who have received at least one dose of study drug and ceased participation in any Phase 2B or 3 randomized, controlled or open-label (qualifying) study of CP-690,550 for the treatment of RA,...

Subjects who have received at least one dose of study drug and ceased participation in any Phase 2B or 3 randomized, controlled or open-label (qualifying) study of CP-690,550 for the treatment of RA,...